A citation-based method for searching scientific literature

Erkut Borazanci, Ronald Korn, Winnie S Liang, Carol Guarnieri, Susan Haag, Courtney Snyder, Kristin Hendrickson, Lana Caldwell, Dan Von Hoff, Gayle Jameson. Oncologist 2020
Times Cited: 4







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice.
Cristina Escribano-Díaz, Alexandre Orthwein, Amélie Fradet-Turcotte, Mengtan Xing, Jordan T F Young, Ján Tkáč, Michael A Cook, Adam P Rosebrock, Meagan Munro, Marella D Canny,[...]. Mol Cell 2013
540
25

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
25

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G Martelotto, Charlotte K Y Ng,[...]. Clin Cancer Res 2017
105
25

Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.
Ronan Russell, Lukas Perkhofer, Stefan Liebau, Qiong Lin, André Lechel, Fenja M Feld, Elisabeth Hessmann, Jochen Gaedcke, Melanie Güthle, Martin Zenke,[...]. Nat Commun 2015
69
25

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Andrew J Aguirre, Jonathan A Nowak, Nicholas D Camarda, Richard A Moffitt, Arezou A Ghazani, Mehlika Hazar-Rethinam, Srivatsan Raghavan, Jaegil Kim, Lauren K Brais, Dorisanne Ragon,[...]. Cancer Discov 2018
130
25

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Kim A Reiss, Rosemarie Mick, Mark H O'Hara, Ursina Teitelbaum, Thomas B Karasic, Charles Schneider, Stacy Cowden, Traci Southwell, Janae Romeo, Natallia Izgur,[...]. J Clin Oncol 2021
15
25

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W T Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M Richards, Duncan I Jodrell. Mol Cancer Ther 2018
43
25

Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair.
Nicole Bennardo, Anita Cheng, Nick Huang, Jeremy M Stark. PLoS Genet 2008
535
25

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Kyle C Cuneo, Meredith A Morgan, Vaibhav Sahai, Matthew J Schipper, Leslie A Parsels, Joshua D Parsels, Theresa Devasia, Mahmoud Al-Hawaray, Clifford S Cho, Hari Nathan,[...]. J Clin Oncol 2019
63
25

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Claudia Winkler, Joshua Armenia, Gemma N Jones, Luis Tobalina, Matthew J Sale, Tudor Petreus, Tarrion Baird, Violeta Serra, Anderson T Wang, Alan Lau,[...]. Br J Cancer 2021
12
25

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly,[...]. Cancer Discov 2013
302
25

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
25

The Fanconi anaemia pathway: new players and new functions.
Raphael Ceccaldi, Prabha Sarangi, Alan D D'Andrea. Nat Rev Mol Cell Biol 2016
341
25

Roles of ATM and ATR in DNA double strand breaks and replication stress.
Rhys M Williams, Xiaodong Zhang. Prog Biophys Mol Biol 2021
4
25

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells.
Ralph Zellweger, Damian Dalcher, Karun Mutreja, Matteo Berti, Jonas A Schmid, Raquel Herrador, Alessandro Vindigni, Massimo Lopes. J Cell Biol 2015
345
25

NCCN Guidelines Updates: Pancreatic Cancer.
Margaret A Tempero. J Natl Compr Canc Netw 2019
86
25

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti. J Hematol Oncol 2020
20
25

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
25

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017
151
25

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.
Siang-Boon Koh, Aurélie Courtin, Richard J Boyce, Robert G Boyle, Frances M Richards, Duncan I Jodrell. Cancer Res 2015
44
25

Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Doga C Gulhan, Jake June-Koo Lee, Giorgio E M Melloni, Isidro Cortés-Ciriano, Peter J Park. Nat Genet 2019
66
25

A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Joan M Romero, Barbara Grünwald, Gun-Ho Jang, Prashant P Bavi, Aaditeya Jhaveri, Mehdi Masoomian, Sandra E Fischer, Amy Zhang, Robert E Denroche, Ilinca M Lungu,[...]. Clin Cancer Res 2020
23
25

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma,[...]. Nat Commun 2020
35
25

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I Harrell, Giada V Zapparoli, Alison Hadley, Robert Holian, Emma Boehm,[...]. Nat Commun 2018
87
25

DNA interstrand crosslink repair and cancer.
Andrew J Deans, Stephen C West. Nat Rev Cancer 2011
618
25

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.
Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, Katherine A Hoadley, Naim U Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung,[...]. Nat Genet 2015
747
25

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
25

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer,[...]. Mol Cancer Ther 2020
46
25

Homologous recombination and the repair of DNA double-strand breaks.
William Douglass Wright, Shanaya Shital Shah, Wolf-Dietrich Heyer. J Biol Chem 2018
222
25

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Philip M Reaper, Matthew R Griffiths, Joanna M Long, Jean-Damien Charrier, Somhairle Maccormick, Peter A Charlton, Julian M C Golec, John R Pollard. Nat Chem Biol 2011
384
25

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim,[...]. Mol Cancer Ther 2017
55
25

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Lola Rahib, Benjamin D Smith, Rhonda Aizenberg, Allison B Rosenzweig, Julie M Fleshman, Lynn M Matrisian. Cancer Res 2014
25

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Talia Golan, Alex Barenboim, Guy Lahat, Ido Nachmany, Yacov Goykhman, Einat Shacham-Shmueli, Naama Halpern, Eli Brazowski, Ravit Geva, Ido Wolf,[...]. Ann Surg Oncol 2020
22
25

A recurrent mutation in PALB2 in Finnish cancer families.
Hannele Erkko, Bing Xia, Jenni Nikkilä, Johanna Schleutker, Kirsi Syrjäkoski, Arto Mannermaa, Anne Kallioniemi, Katri Pylkäs, Sanna-Maria Karppinen, Katrin Rapakko,[...]. Nature 2007
314
25

Replication stress in Mammalian cells and its consequences for mitosis.
Camille Gelot, Indiana Magdalou, Bernard S Lopez. Genes (Basel) 2015
60
25

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
627
25

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Rachna T Shroff, Andrew Hendifar, Robert R McWilliams, Ravit Geva, Ron Epelbaum, Lindsey Rolfe, Sandra Goble, Kevin K Lin, Andrew V Biankin, Heidi Giordano,[...]. JCO Precis Oncol 2018
87
25

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.
Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
129
25

Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Tetsuhito Muranaka, Masaki Kuwatani, Yoshito Komatsu, Kentaro Sawada, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Satoshi Yuki, Yoshimasa Kubota, Kimitoshi Kubo, Shuhei Kawahata,[...]. J Gastrointest Oncol 2017
41
25

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Gabriele Zoppoli, Marie Regairaz, Elisabetta Leo, William C Reinhold, Sudhir Varma, Alberto Ballestrero, James H Doroshow, Yves Pommier. Proc Natl Acad Sci U S A 2012
152
25

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Raphael Ceccaldi, Jessica C Liu, Ravindra Amunugama, Ildiko Hajdu, Benjamin Primack, Mark I R Petalcorin, Kevin W O'Connor, Panagiotis A Konstantinopoulos, Stephen J Elledge, Simon J Boulton,[...]. Nature 2015
394
25

Exploiting DNA Replication Stress for Cancer Treatment.
Tajinder Ubhi, Grant W Brown. Cancer Res 2019
56
25

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu,[...]. Cancer Discov 2017
205
25

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
171
25

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Weiqing Jing, Donna McAllister, Emily P Vonderhaar, Katie Palen, Matthew J Riese, Jill Gershan, Bryon D Johnson, Michael B Dwinell. J Immunother Cancer 2019
35
25

Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
Nicholas J Roberts, Alexis L Norris, Gloria M Petersen, Melissa L Bondy, Randall Brand, Steven Gallinger, Robert C Kurtz, Sara H Olson, Anil K Rustgi, Ann G Schwartz,[...]. Cancer Discov 2016
179
25

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
158
25

Synthetic lethality as an engine for cancer drug target discovery.
Alan Huang, Levi A Garraway, Alan Ashworth, Barbara Weber. Nat Rev Drug Discov 2020
107
25

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
46
25

A Genetic Map of the Response to DNA Damage in Human Cells.
Michele Olivieri, Tiffany Cho, Alejandro Álvarez-Quilón, Kejiao Li, Matthew J Schellenberg, Michal Zimmermann, Nicole Hustedt, Silvia Emma Rossi, Salomé Adam, Henrique Melo,[...]. Cell 2020
90
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.